The mechanism study of YZG-331 on sedative and hypnotic effects

YZG-331 is a synthetic novel derivates of N-6-(4-hydroxybenzyl) adenine riboside (NHBA), which has potent sedative and hypnotic effects based on our previous study. We are now aiming to investigate the mechanism of YZG-331. In this research, the behavioral studies showed that YZG-331 (4, 8, 16 mg/kg, i.g.) could reduce the spontaneous locomotor activity in mice, which could be blocked by AM (non-selective adenosine receptor antagonist), DPCPX (adenosine A(1) receptor (A(1)R) antagonist), and SCH58261 (adenosine A(2a) receptor (A(2a)R) antagonist). Moreover, YZG-331 no longer exerted sedative effect in A(1)R or A(2a)R knockdown mice. YZG-331 (2.5, 5, 10 mg/kg, i.g.) prolonged sleeping time in pentobarbital sodium treated mice, which can be prevented by DPCPX or SCH58261. The above results demonstrated that YZG-331 exerted sedative and hypnotic effects through A(1)R and A(2a)R. In addition, it was found that YZG-331 (25, 50, 100 mu M) decreased intracellular calcium level and YZG-331 (10 mg/kg, i.g.) decreased CaMKII phosphorylation (pCaMKII) level in mouse hypothalamus and cortex. In summary, this study indicated that activation of A(1)R/ A(2a)R and down regulation of Ca2+-CaMKII signaling pathway were involved in the sedative and hypnotic effects of YZG-331.

Automated summary

YZG-331 exerts sedative and hypnotic effects through the activation of A(1)R and A(2a)R, as well as the down regulation of the Ca2+-CaMKII signaling pathway.